Small but heading for a big time

NANOBIOTIX announces the registration of its « *document de base* » in preparation of its planned IPO on the regulated market of NYSE Euronext in Paris*

Paris, September 11, 2012 – NANOBIOTIX, a French company and nanomedicine pioneer developing NanoXray, a revolutionary therapeutic approach to local cancer treatment, today announces the registration of its *document de base* by the *Autorité des Marchés Financiers* (AMF), the French stock market authority, under reference number I. 12-043 on September 10, 2012, in preparation of its planned IPO on the regulated market of NYSE Euronext in Paris*.



Nanomedicine: A breakthrough approach for local cancer treatment

Cancer is one of the leading causes of death worldwide and accounted for 13% of all deaths in 2008. Radiotherapy has been widely used in most oncology indications for decades. About 50 to 60% of cancer patients receive radiotherapy, either independently or in combination, at some point of their treatment regime. Today, many cancer patients do not receive doses sufficient for tumor destruction, respond insufficiently or not at all to treatments, or even develop resistance to these treatments. In order to obtain greater radiotherapy efficacy, the dose delivered to the tumor must be increased without increasing its effect on healthy tissues. The fundamental goal of Nanobiotix is to provide a solution to the following question: "How to increase the dose delivered to the tumor without increasing it in healthy tissue?"

NanoXray technology could provide significant progress in radiotherapy

Nanobiotix, pioneer and leader in nanomedicine, has developed a revolutionary concept dedicated to the local treatment of cancer. Nanobiotix is focused on the development of NanoXray, a pipeline of patented products, which are based on a physical mechanism of action: Nanoparticles interact with X-rays and maximize the effect of radiotherapy within tumor cells. NanoXray products enhance the radiotherapy efficacy in the tumor without increasing healthy tissues damages. NanoXray nanoparticles could overcome one of the greatest limitations of radiotherapy: the impossibility of delivering a radiation dose sufficient

***Subject to market conditions and to the AMF granting its visa on the prospectus relating to such offering.**

to reliably destroy the tumor only. At present, this is not feasible because of side effects in the surrounding healthy tissues.

A disruptive therapeutic approach for all cancers treated by radiotherapy

The NanoXray portfolio currently consists of three products designed to meet specific clinical needs for different cancers:

First product under clinical evaluation:

- NBTXR3: designed for direct injection into the tumor. Market entry planned for 2017.

2 products establishing growth drivers in medium term:

- NBTX-IV: designed for intravenous injection where tumor cannot be accessed using intra-tumoral injection.
- NBTX-TOPO: formulated as a gel to be applied during surgery after removal of the tumor.

NanoXray technology is seamlessly compatible with current protocols and requires only one injection prior to the first radiotherapy cycle with no change in surgery and radiotherapy procedures. In addition, the inclusion of NanoXray technology is fully compatible with standard radiotherapy equipment, available in practically all hospitals throughout the world.

A considerable market potential

The NanoXray portfolio of Nanobiotix has the potential to address a considerable part of the population of cancer patients treated by radiotherapy. The three NanoXray products could reach a total target population of close to 1 million patients in the seven largest oncology markets (United States, Japan, Germany, France, England, Italy and Spain), representing a huge potential market. Moreover, Nanobiotix plans to extend the commercialization of its products in Brazil, Russia, India, China and South Africa, thus expanding its market to 2 million potential patients.

A collaboration agreement already signed with a pharma company, PharmaEngine

In August 2012, Nanobiotix granted PharmaEngine exclusive rights to develop and commercialize NBTXR3 in the Asian-Pacific region. PharmaEngine is a biopharmaceutical company focuses on the development of new drugs for the treatment of cancer and Asian prevalent diseases. Pursuant to this agreement, Nanobiotix received an initial upfront payment of US$ 1 million on August 21, 2012 and is eligible for further development and commercialization milestone payments which may amount to a total of US$ 56 million plus tiered, up to double-digit royalties on net product sales in the Asian-Pacific region. PharmaEngine is further funding the clinical development of NBTXR3 in three different indications with the goal to commence clinical studies in two indications before February 2014. The studies conducted by PharmaEngine will add to the ongoing European Phase I study in soft tissue sarcoma and another Phase I study to be initiated by Nanobiotix in 2013. This agreement is a major step for the company and should accelerate the development of NBTXR3 in Asia-Pacific area.

●●●

Availability of the *document de base* - The *document de base* source document registered on September 10, 2012 under reference number I. 12-043 is available free of charge on request from Nanobiotix, 60 rue de Wattignies, 75012 Paris, France, as well as on the AMF website (www.amf-france.org) and the Nanobiotix website (www.nanobiotix.com).

Risk factors – Nanobiotix draws the public's attention to section 4 "Risk factors" of the *document de base* registered with the AMF, in particular to the risk factors 4.6.2 "Liquidity risk and need for additional financing" and 4.1.1 "Risk in clinical development and risk in use of the company products".

About NANOBIOTIX,

Nanobiotix, pioneer and leader in nanomedicine, has developed a revolutionary concept dedicated to the local treatment of cancer. Nanobiotix is focused on the development of NanoXray, a pipeline of patented products, which are based on the physical mechanism of action of the nanoparticles interacting with X-rays and maximizing radiation effect into tumor cells. NanoXray products enhance the efficacy of the radiotherapy in the tumor without increasing healthy tissues damages. NanoXray products can be used with existing standard radiation equipments available in almost every hospital world-wide.

Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo that was incorporated in 2003 and has been primarily funded by leading European venture capital firms. The company has more than 30 employees and is based in Paris, France. Nanobiotix's objective is to enhance its leading position in the nanomedicine field on the main oncology markets. Its pipeline of universal products enable to target the major indications of cancers (breast cancer, prostate cancer, lung cancer…), leading to a potential market of several billion dollars. Thanks to the physical based mechanism of action of its nanoparticles, Nanobiotix brings out a unique business model with much lower risk than classic drug development, enabling a faster and less expensive time to market.

●●●

CONTACTS

Nanobiotix
Laurent Levy
CEO and Co-founder
Tel :+33(0) 40 26 04 70
contact@nanobiotix.com

*New***Cap.**
Financial communication and investor relations
Louis-Victor Delouvrier / Emmanuel Huynh
Tel :+33(0)1 44 71 98 53
lvdelouvrier@newcap.fr

Yucatan
Press Relations
Annie-Florence Loyer
Tel :+33(0)1 53 63 27 29
afloyer@yucatan.tm.fr

Warning

This press release, and the information that it contains, constitute neither an offer to sell or subscribe nor a solicitation to purchase or subscribe for NANOBIOTIX shares in any countries. No offer of shares is made or will be made in France before the delivery of the visa by the *Autorité des marchés financiers* (the "AMF") on a prospectus composed of the *document de base*and a securities note (*a note d'opération*) which will be subsequently submitted to the AMF.

This press release does not constitute or form a part of any offer to sell or subscribe or solicitation to purchase or subscribe for securities in the United States. The shares or any other securities of NANOBIOTIX may not be offered or sold in the United States unless they are registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or exempt from registration. The shares of NANOBIOTIX have not been and will not be registered under the U.S. Securities Act and NANOBIOTIX does not intend to make any public offer of its shares in the United States.

The distribution of this press release in certain countries may be subject to specific regulations. The persons in possession of this press release shall then get knowledge of any local restrictions and shall comply with these restrictions.

This press release is solely an advertisement and does not constitute a prospectus within the meaning of Directive 2003/71/EC of the European Parliament and the Council of November 4th, 2003, as amended, in particular by Directive 2010/73/EC of the European Parliament and of the Council of November 24, 2010, to the extent such Directive has been transposed in the relevant member State of the European Economic Area (the "Prospectus Directive").

With respect to the member States of the European Economic Area which have implemented the Prospectus Directive, no action has been undertaken or will be undertaken to make an offer to the public of the securities requiring a publication of a prospectus in any member State, other than France. As a result, the shares of NANOBIOTIX may not be offered or will not be offered in any member State other than France, except, pursuant to the exemptions described in article 3(2) of the Prospectus Directive, if they have been transposed by this member State or in any other circumstances not requiring NANOBIOTIX to publish a prospectus as provided under article 3(2) of the Prospectus Directive and/or regulations applicable in this member State.

This press release does not constitute and shall not be considered as constituting a public offer, an offer to purchase or as an intention to solicit the interest of the public for a public offering.

This press release is for distribution only to persons who (i) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the "Financial Promotion Order"), (ii) are persons falling within Article 49(2)(a) to (d) ("high net worth companies, unincorporated associations etc") of the Financial Promotion Order, (iii) are outside the United Kingdom, or (iv) are persons to whom an invitation or inducement to engage in investment activity (within the meaning of section 21 of the Financial Services and Markets Act 2000) in connection with the issue or sale of any securities may otherwise lawfully be communicated or caused to be communicated (all such persons together being referred to as "relevant persons"). This press release is directed only at relevant persons and must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this press release relates is available only to relevant persons and will be engaged in only with relevant persons.

This press release contains forward-looking statements. No guarantee is given as to these forecasts being achieved, which are subject to risks including, in particular, those described in the *document de base* filed with this AMF under number I. 12-043 on September 10, 2012, and to the development of economic conditions, the financial markets and the markets in which Nanobiotix operates.